#Primary Sclerosing Cholangitis (PSC) market size
Explore tagged Tumblr posts
businessindustry · 11 days ago
Text
Primary Sclerosing Cholangitis Market Size, Share and Future News by 2025-2033
Tumblr media
The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the Primary Sclerosing Cholangitis Market?
The global primary sclerosing cholangitis market was valued at US$ 174.9 Million in 2024 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 370.8 Million in 2033.
What are Primary Sclerosing Cholangitis?                                                                                                                                             
Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.
Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389
What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?
The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.
What is included in market segmentation?
The report has segmented the market into the following categories:
By Type
Classic PSC
Variant PSC
PSC Associated with Autoimmune Hepatitis
PSC with Cholangiocarcinoma
By Treatment Type
Ursodeoxycholic Acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others
By Route of Administration
Oral
Parental
Others
By End-User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Poland
Benelux
Nordic
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
ASEAN
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
South Africa
United Arab Emirates
Israel
Rest of MEA
Who are the key players operating in the industry?
The report covers the major market players including:
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceutical Ltd.
Cymabay Therapeutics
Pliant Therapeutics
Immunic AG
View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1
0 notes
anjaliavhad · 5 months ago
Text
0 notes
delveinsight12 · 1 year ago
Text
Primary Sclerosing Cholangitis Market Growth Anticipated: Primary Sclerosing Cholangitis Set for Robust Expansion up to 2032, Major Players Include HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics
In the market landscape of Primary Sclerosing Cholangitis, an impressive surge is expected during the study period spanning 2019 to 2032, according to latest report titled  “Primary Sclerosing Cholangitis Market Insights, Epidemiology and Market Forecast, 2032” from DelveInsight. Noteworthy advancements are projected, fueled not only by existing approved therapies but also by the introduction of emerging treatments slated for launch between 2023 and 2032, incremental increase in incidence is reported to impact the market significantly.
The report sheds light on Primary Sclerosing Cholangitis current treatment practices, upcoming drugs in the Primary Sclerosing Cholangitis pipeline, market shares of individual therapies, and the anticipated trajectory of the Primary Sclerosing Cholangitis market size from 2019 to 2032 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan).
Driving Forces Behind the Primary Sclerosing Cholangitis Market Growth
The overall market of Primary Sclerosing Cholangitis (PSC) is expected to boost due to the expected launch of emerging therapy in the forecasted period (2023–2032).
Discover the Anticipated Evolution and Growth of the Market @ Primary Sclerosing Cholangitis Therapeutics Market Forecast
Therapeutic Advancements and Emerging Treatments:
Primary Sclerosing Cholangitis Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, and others, are actively engaged in developing novel drugs for potential market entry.
Primary Sclerosing Cholangitis Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Primary Sclerosing Cholangitis. Therapies such as HTD1801, Norursodeoxycholic acid, A3907, PLN-74809 (bexotegrast), and others are driving the Primary Sclerosing Cholangitis market.
Primary Sclerosing Cholangitis Epidemiological Trends and Patient Demographics:
According to DelveInsight analysis, in the US the diagnosed prevalence of Primary Sclerosing Cholangitis is higher in males than females.
According to DelveInsight analysis, in EU4 and the UK, the symptomatic cases of Primary Sclerosing Cholangitis are higher than asymptomatic cases. 
Report Features
Details
Geography Coverage
7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Study Period
2019-2032
Market Size
~USD 113 million in 2022
Key Companies
HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, and others.
The market size of primary sclerosing cholangitis (PSC) is anticipated to increase during the study period, 2019–2032. The expected launch of therapies will lead to change in market dynamics during the forecast period (2023-2032).
Leading Primary Sclerosing Cholangitis Companies and Emerging Drugs: Pioneering companies such as HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, among others, are actively developing novel drugs for potential entry into the Primary Sclerosing Cholangitis market.
Primary Sclerosing Cholangitis Therapeutic Landscape: Key therapies identified for Primary Sclerosing Cholangitis treatment include HTD1801, Norursodeoxycholic acid, A3907, PLN-74809 (bexotegrast), and more.
Primary Sclerosing Cholangitis Overview:
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation, scarring (fibrosis), and narrowing of the bile ducts inside and outside the liver. Over time, this progressive condition can lead to liver damage, cirrhosis, and complications such as liver failure, bile duct infections (cholangitis), and an increased risk of bile duct and liver cancer (cholangiocarcinoma).
Cause: The exact cause of PSC is not fully understood. It is believed to involve an autoimmune component, where the body's immune system mistakenly attacks the bile ducts, leading to inflammation and scarring. PSC is also associated with other autoimmune conditions such as inflammatory bowel disease (IBD), particularly ulcerative colitis.
Symptoms: Many individuals with PSC initially have no symptoms (asymptomatic), but as the disease progresses, they may experience fatigue, itching (pruritus), jaundice (yellowing of the skin and eyes), abdominal pain, fever, weight loss, and complications related to bile duct obstruction or liver damage.
Diagnosis: Diagnosis of PSC involves a combination of blood tests, imaging studies (such as MRI or ERCP), and sometimes a liver biopsy to assess liver tissue for characteristic changes. Additionally, colonoscopy or other tests may be performed to evaluate for associated inflammatory bowel disease.
Treatment: There is no cure for PSC, and treatment primarily focuses on managing symptoms, slowing disease progression, and preventing complications. Medications may be prescribed to relieve itching, manage inflammation, and address complications. In some cases, endoscopic or surgical procedures may be necessary to relieve bile duct blockages.
Monitoring and Complications: Regular monitoring is crucial for individuals with PSC to assess disease progression, manage symptoms, and screen for complications such as liver cirrhosis, bile duct cancer, and other liver-related problems. Liver transplant may be considered for individuals with advanced PSC and severe liver damage or complications.
PSC is a chronic condition that requires ongoing care and monitoring by healthcare providers specializing in gastroenterology or hepatology. Management often involves a multidisciplinary approach, including gastroenterologists, hepatologists, surgeons, and other healthcare professionals, to address various aspects of the disease and optimize treatment strategies.
While treatment can help manage symptoms and slow disease progression, PSC is associated with a risk of complications and may require vigilant long-term management to improve quality of life and reduce the risk of serious liver-related issues.
Key Facts Primary Sclerosing Cholangitis Market Report:
The Primary Sclerosing Cholangitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
According to DelveInsight analysis, the United States accounted for the highest market size of $78 million, with significant market share of PSC in 2022 in the 7MM. The market size of the 7MM is anticipated to increase in the forecast period due to the expected launch of emerging therapy.
Among EU4 and the UK, Germany, Italy, and the UK accounted for the highest market size with approximately 25% each of the total market size in the EU4 and the UK in the year 2022, whileSpainaccounted for the lowest market in the year 2022.
As per DelveInsight estimates, the market size in Japan was approximately USD 4 million in 2022. These numbers are expected to increase during the forecasted period.
Primary Sclerosing Cholangitis Epidemiology Insights:
In 2022, there were about 9,171 diagnosed asymptomatic cases of PSC and 11,038 diagnosed symptomatic cases PSC, in the EU4 and the UK.
As per DelveInsight’s analysts, in Japan, there were approximately 2,443 diagnosed prevalent cases of PSC in the year 2022 accounting for nearly 5% of the total diagnosed prevalent cases of PSC in the 7MM.
Primary Sclerosing Cholangitis Epidemiology Segmentation:
The Primary Sclerosing Cholangitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
• Total Prevalence of Primary Sclerosing Cholangitis
• Prevalent Cases of Primary Sclerosing Cholangitis by severity
• Gender-specific Prevalence of Primary Sclerosing Cholangitis
• Diagnosed Cases oF Primary Sclerosing Cholangitis
For in-depth insights, access the full report @ Primary Sclerosing Cholangitis Market Outlook 2032
Related Reports:
Primary Sclerosing Cholangitis Epidemiology Forecast
Primary Sclerosing Cholangitis Epidemiology Forecast report delivers an in-depth understanding of the Primary Sclerosing Cholangitis, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Primary Sclerosing Cholangitis Pipeline Insight
Primary Sclerosing Cholangitis Pipeline Insight report provides comprehensive insights about companies and pipeline drugs in the Primary Sclerosing Cholangitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. 
Healthcare Consulting and Market Research Services by DelveInsight
Upgrade your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics @  Healthcare Market Research Services
About DelveInsight:
DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.
Connect with DelveInsight:
LinkedIn | Facebook | Twitter
Contact Us:
Kritika Rehani
+91-9650213330
www.delveinsight.com
0 notes
delicatemagazinedreamer · 2 years ago
Text
Global Cervical Spondylosis Treatment Market Is Estimated To Witness High Growth Owing To Rising Incidences of Cervical Spondylosis
Tumblr media
The global Cholangiocarcinoma Market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8% over the forecast period 2021-2028, as highlighted in the new report published by Coherent Market Insights. Cholangiocarcinoma, also known as bile duct cancer, is a rare and aggressive form of cancer that affects the bile ducts. The market for Cholangiocarcinoma is driven by the increasing incidences of the disease and the need for effective treatment options. Market Overview: Cholangiocarcinoma is a deadly cancer that arises from the cells lining the bile ducts, which are responsible for carrying bile from the liver to the small intestine. This cancer is difficult to diagnose in its early stages and is often detected at an advanced stage when treatment options are limited. The market for Cholangiocarcinoma is driven by the need for targeted therapies and innovative treatment approaches to improve patient outcomes. Currently, there are limited treatment options available for patients with Cholangiocarcinoma, which creates a significant unmet need in the market. Market Key Trends: One key trend in the Cholangiocarcinoma Market is the increasing focus on precision medicine and targeted therapies. Precision medicine involves tailoring treatment plans based on an individual's genetic makeup, allowing for more personalized and effective treatments. Several pharmaceutical companies are investing in research and development to identify specific genetic mutations and biomarkers associated with Cholangiocarcinoma to develop targeted therapies. For example, Incyte Corporation and QED Therapeutics are conducting clinical trials for their targeted therapy, pemigatinib, which has shown promising results in patients with locally advanced or metastatic Cholangiocarcinoma. PEST Analysis: - Political: Government initiatives and regulations play a crucial role in the development and availability of treatments for Cholangiocarcinoma. Governments are increasingly focusing on improving cancer care and funding research programs.
- Economic: The economic impact of Cholangiocarcinoma is significant, as it requires long-term treatment and care. The high cost of treatment options and supportive care pose challenges for patients and healthcare systems.
- Social: The increasing awareness about Cholangiocarcinoma among the general population and healthcare professionals is driving early detection and diagnosis. Support groups and patient advocacy organizations are providing support and resources to patients and their families.
- Technological: Advances in diagnostic technologies, such as molecular testing and imaging techniques, are enabling early detection and accurate diagnosis of Cholangiocarcinoma. Additionally, the development of targeted therapies and immunotherapies is revolutionizing the treatment landscape for this aggressive cancer. Key Takeaways: In terms of market size, the global Cholangiocarcinoma market is expected to witness high growth, exhibiting a CAGR of 12.8% over the forecast period, due to increasing incidences of the disease. The rising prevalence of risk factors such as primary sclerosing cholangitis (PSC), hepatitis B and C infections, and exposure to certain chemicals and toxins are contributing to the growing incidence of Cholangiocarcinoma. Moreover, the lack of effective treatment options for this aggressive cancer creates opportunities for pharmaceutical companies to develop innovative therapies to improve patient outcomes. Key players operating in the global Cholangiocarcinoma market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc. These companies are focusing on strategic collaborations, clinical trials, and research and development activities to develop effective treatment options for Cholangiocarcinoma.
0 notes
kritikarehani · 5 years ago
Text
Primary Sclerosing Cholangitis (PSC) Market Trends 2030
Primary Sclerosing Cholangitis (PSC) is a condition that affects the bile ducts. It occurs because of inflammation in the bile ducts (cholangitis) that leads to scarring (sclerosis) and narrowing of the ducts. As a result, bile cannot be released to the gallbladder and small intestine, and it builds up in the liver.
DelveInsight's "Primary Sclerosing Cholangitis (PSC) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis (PSC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Tumblr media
The Primary Sclerosing Cholangitis (PSC) market report provides current treatment practices, emerging drugs, Primary Sclerosing Cholangitis (PSC) market share of the individual therapies, current and forecasted Primary Sclerosing Cholangitis (PSC) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Primary Sclerosing Cholangitis (PSC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered
· The United States
· EU5 (Germany, France, Italy, Spain, and the United Kingdom)
· Japan
Study Period: 2017-2030
Download sample pages: https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market
Primary Sclerosing Cholangitis (PSC) Disease Understanding and Treatment Algorithm
Primary Sclerosing Cholangitis is thought to arise from a combination of genetic and environmental factors. Researchers believe that genetic changes play a role in this condition because it often occurs in several members of a family and because immediate family members of someone with primary sclerosing cholangitis have an increased risk of developing the condition.  
The symptoms associated with PSC include fatigue and itching (pruritus), followed by yellowing of the skin, mucous membranes, and whites of the eyes (jaundice). Other symptoms may include losing weight without trying, poor appetite, fever, and pain in the abdomen.
The DelveInsight Primary Sclerosing Cholangitis (PSC) market report gives a thorough understanding of the Primary Sclerosing Cholangitis (PSC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 
Diagnosis 
This segment of the report covers the detailed diagnostic methods or tests for Primary Sclerosing Cholangitis (PSC). 
Treatment 
It covers the details of conventional and current medical therapies available in the Primary Sclerosing Cholangitis (PSC) market for the treatment of the condition. It also provides Primary Sclerosing Cholangitis (PSC) treatment algorithms and guidelines in the United States, Europe, and Japan. 
Request for sample pages: https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market
Primary Sclerosing Cholangitis (PSC) Epidemiology  
The Primary Sclerosing Cholangitis (PSC) epidemiology division provide insights about historical and current Primary Sclerosing Cholangitis (PSC) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  
Key facts:
• Primary sclerosing cholangitis is a rare disorder that affects males twice as often as females. Although it may affect individuals of any age, the disorder most often occurs in middle-aged adults.
• The exact incidence and prevalence of the disorder is unknown. One estimate places the incidence at approximately 1 person per each 100,000 in the general population in the United States or Europe.
Primary Sclerosing Cholangitis (PSC) Drug Chapters
In the coming years, the competitive landscape for the Primary Sclerosing Cholangitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
Major players, such as Gilead Sciences, HighTide Therapeutics, Tobira Therapeutics and NGM Biopharmaceuticals are involved in developing therapies for Primary Sclerosing Cholangitis. Launch of emerging therapies, such as GS-9674 (Gilead Sciences), HTD1801 (HighTide Therapeutics), Cenicriviroc (Tobira Therapeutics) and NGM282 (NGM Biopharmaceuticals) will significantly impact the Primary Sclerosing Cholangitis market during the study period (2017–2030).  
Drug chapter segment of the Primary Sclerosing Cholangitis (PSC) report encloses the detailed analysis of Primary Sclerosing Cholangitis (PSC) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Primary Sclerosing Cholangitis (PSC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs 
The report provides the details of the marketed product available for Primary Sclerosing Cholangitis (PSC) treatment. 
Primary Sclerosing Cholangitis (PSC) Emerging Drugs 
The report provides the details of the emerging therapies under the late and mid-stage of development for Primary Sclerosing Cholangitis (PSC) treatment. 
Primary Sclerosing Cholangitis (PSC) Market Outlook
The treatment of PSC focuses on managing the complications and monitoring the liver damage. There have been several medications which are studied in people with Primary Sclerosing Cholangitis, but so far none have been found to slow or reverse the liver damage associated with this disease.
The pharmacotherapy is aimed at treating symptoms and managing complications. Immuno-suppressants, bile salts, chelators (eg, cholestyramine for pruritus), and steroids are used in an attempt to control the disease process but have not shown significant benefit. The further treatment depends on the stage and degree of progression of the disease. There are two major treatment goals in PSC: slow or reverse disease progression and management of symptoms of disease progression.
The Primary Sclerosing Cholangitis (PSC) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Primary Sclerosing Cholangitis (PSC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 
According to DelveInsight, Primary Sclerosing Cholangitis (PSC) market in 7MM is expected to change in the study period 2017-2030.
Click here and get access to our full report.
Click here and request to download our sample pages.
0 notes
awesomechrisharry · 4 years ago
Text
Primary Sclerosing Cholangitis Treatment Market: Future Demand, Analysis & Outlook to 2025
The research report on Primary Sclerosing Cholangitis Treatment market as well as industry is an in-depth study that provides detailed information of leading players, qualitative analysis and quantitative analysis, types & end-users; historical figures, region analysis, market technology landscape & restraints, strategic planning, and a precise section for the effect of Covid-19 on the industry. Our research analysts intensively determine the significant outlook of the global Primary Sclerosing Cholangitis Treatment market study with regard to primary research & secondary research and they have represented it in the form of figures, pie charts, tables & other pictorial representations for better understanding.
To Know More Details About This Report, Get Sample @ http://www.acquiremarketresearch.com/sample-request/348428
The report on Primary Sclerosing Cholangitis Treatment market claims this industry to emerge as one of the most lucrative spaces in the ensuing years, exhibiting a modest growth rate over the forecast period. Enumerating a highly exhaustive outline of Primary Sclerosing Cholangitis Treatment Market size, this report is also inclusive of the total valuation that the Primary Sclerosing Cholangitis Treatment industry presently holds, a brief segmentation of this market and Primary Sclerosing Cholangitis Treatment market growth opportunities of this industry in addition to its geographical expanse.
Major Key Players Covered In This Report:
Allergan, Glenmark, Impax Laboratories, Mylan, Teva Pharmaceuticals, Dr. Falk Pharma, Daewoong Pharmaceutical, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Bruschettini, Shanghai Pharma, Grindeks, Acorda Therapeutics, Gilead Sciences, Intercept Pharmaceuticals, Shire Plc, NGM Biopharmaceuticals, Conatus Pharmaceuticals, Durect Corporation, Sirnaomics, Shenzhen HighTide Biopharmaceuticals
Primary Sclerosing Cholangitis Treatment Market Analysis by 2020
This research report based on ‘Primary Sclerosing Cholangitis Treatment market’ and available with Acquire Market Research includes latest and upcoming market trends in addition to the global spectrum of the ‘Primary Sclerosing Cholangitis Treatment market’ that includes numerous regions. Moreover, the research also expands on intricate details pertaining to contributions by key Manufacturers, import & export, demand and supply analysis as well as industry size, share growth of the Primary Sclerosing Cholangitis Treatment industry.
The specified segments and sub-sections of the market are explained below:
By Product Type:
Liver Transplantation Operation, UDCA Drugs, PSC Drugs
By Application/End-user:
Hospital, Clinics, Other
By country/region:
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Check Discount @ http://www.acquiremarketresearch.com/discount-request/348428
Frequently Asked Questions About This Market Research Report:
What are the latest trends, and strategies followed by leadings companies?
What is the market share of each Major Players specified in this report?
What are opportunities for Primary Sclerosing Cholangitis Treatment investors and market aspirants?
What are the major product types and which applications are known?
Which countries are analyzed in this report?
What is the market size, and demand for Primary Sclerosing Cholangitis Treatment on a global level?
What is the CAGR value of Primary Sclerosing Cholangitis Treatment Market?
About Us:
Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.
Contact Us:
http://www.acquiremarketresearch.com/
0 notes
stanleystangele · 5 years ago
Text
Primary Sclerosing Cholangitis Treatment Market: Future Demand,  Analysis & Outlook to 2025
The research report on Primary Sclerosing Cholangitis Treatment market as well as industry is an in-depth study that provides detailed information of leading players, qualitative analysis and quantitative analysis, types & end-users; historical figures, region analysis, market technology landscape & restraints, strategic planning, and a precise section for the effect of Covid-19 on the industry. Our research analysts intensively determine the significant outlook of the global Primary Sclerosing Cholangitis Treatment market study with regard to primary research & secondary research and they have represented it in the form of figures, pie charts, tables & other pictorial representations for better understanding.
To Know More Details About This Report, Get Sample @ http://www.acquiremarketresearch.com/sample-request/347806
The report on Primary Sclerosing Cholangitis Treatment market claims this industry to emerge as one of the most lucrative spaces in the ensuing years, exhibiting a modest growth rate over the forecast period. Enumerating a highly exhaustive outline of Primary Sclerosing Cholangitis Treatment Market size, this report is also inclusive of the total valuation that the Primary Sclerosing Cholangitis Treatment industry presently holds, a brief segmentation of this market and Primary Sclerosing Cholangitis Treatment market growth opportunities of this industry in addition to its geographical expanse.
Major Key Players Covered In This Report:
Allergan, Glenmark, Impax Laboratories, Mylan, Teva Pharmaceuticals, Dr. Falk Pharma, Daewoong Pharmaceutical, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Bruschettini, Shanghai Pharma, Grindeks, Acorda Therapeutics, Gilead Sciences, Intercept Pharmaceuticals, Shire Plc, NGM Biopharmaceuticals, Conatus Pharmaceuticals, Durect Corporation, Sirnaomics, Shenzhen HighTide Biopharmaceuticals
Primary Sclerosing Cholangitis Treatment Market Analysis by 2020
This research report based on ‘Primary Sclerosing Cholangitis Treatment market’ and available with Acquire Market Research includes latest and upcoming market trends in addition to the global spectrum of the ‘Primary Sclerosing Cholangitis Treatment market’ that includes numerous regions. Moreover, the research also expands on intricate details pertaining to contributions by key Manufacturers, import & export, demand and supply analysis as well as industry size, share growth of the Primary Sclerosing Cholangitis Treatment industry.
The specified segments and sub-sections of the market are explained below:
By Product Type:
Liver Transplantation Operation, UDCA Drugs, PSC Drugs
By Application/End-user:
Hospital, Clinics, Other
By country/region:
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Check Discount @ http://www.acquiremarketresearch.com/discount-request/347806
Frequently Asked Questions About This Market Research Report:
What are the latest trends, and strategies followed by leadings companies?
What is the market share of each Major Players specified in this report?
What are opportunities for Primary Sclerosing Cholangitis Treatment investors and market aspirants?
What are the major product types and which applications are known?
Which countries are analyzed in this report?
What is the market size, and demand for Primary Sclerosing Cholangitis Treatment on a global level?
What is the CAGR value of Primary Sclerosing Cholangitis Treatment Market?
About Us:
Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.
Contact Us:
http://www.acquiremarketresearch.com/
0 notes
businessindustry · 2 months ago
Text
Primary Sclerosing Cholangitis Market Size, Share and Future News by 2025-2033
Tumblr media
The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the Primary Sclerosing Cholangitis Market?
The global primary sclerosing cholangitis market was valued at US$ 174.9 Million in 2024 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 370.8 Million in 2033.
What are Primary Sclerosing Cholangitis?                                                                                                                                             
Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.
Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389
What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?
The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.
What is included in market segmentation?
The report has segmented the market into the following categories:
By Type
Classic PSC
Variant PSC
PSC Associated with Autoimmune Hepatitis
PSC with Cholangiocarcinoma
By Treatment Type
Ursodeoxycholic Acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others
By Route of Administration
Oral
Parental
Others
By End-User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Poland
Benelux
Nordic
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
ASEAN
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
South Africa
United Arab Emirates
Israel
Rest of MEA
Who are the key players operating in the industry?
The report covers the major market players including:
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceutical Ltd.
Cymabay Therapeutics
Pliant Therapeutics
Immunic AG
View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1
0 notes
businessindustry · 10 months ago
Text
Primary Sclerosing Cholangitis Market Size, Share and Future News by 2032
Tumblr media
The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market Trends share, size, growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the Primary Sclerosing Cholangitis Market?
The global primary sclerosing cholangitis market was valued at US$ 162.3 Million in 2023 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 319.1 Mn in 2032.
What are Primary Sclerosing Cholangitis?                                                                                                                                                                            
Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.
Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389
What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?
The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.
What is included in market segmentation?
The report has segmented the market into the following categories:
By Type
Classic PSC
Variant PSC
PSC Associated with Autoimmune Hepatitis
PSC with Cholangiocarcinoma
By Treatment Type
Ursodeoxycholic Acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others
By Route of Administration
Oral
Parental
Others
By End-User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Poland
Benelux
Nordic
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
ASEAN
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
South Africa
United Arab Emirates
Israel
Rest of MEA
Who are the key players operating in the industry?
The report covers the major market players including:
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceutical Ltd.
Cymabay Therapeutics
Pliant Therapeutics
Immunic AG
View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1
0 notes
delicatemagazinedreamer · 2 years ago
Text
Global Cholangiocarcinoma Market Is Estimated To Witness High Growth Owing To Rising Incidences of the Disease
Tumblr media
The global Cholangiocarcinoma Market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8% over the forecast period 2021-2028, as highlighted in the new report published by Coherent Market Insights. Cholangiocarcinoma, also known as bile duct cancer, is a rare and aggressive form of cancer that affects the bile ducts. The market for Cholangiocarcinoma is driven by the increasing incidences of the disease and the need for effective treatment options. Market Overview: Cholangiocarcinoma is a deadly cancer that arises from the cells lining the bile ducts, which are responsible for carrying bile from the liver to the small intestine. This cancer is difficult to diagnose in its early stages and is often detected at an advanced stage when treatment options are limited. The market for Cholangiocarcinoma is driven by the need for targeted therapies and innovative treatment approaches to improve patient outcomes. Currently, there are limited treatment options available for patients with Cholangiocarcinoma, which creates a significant unmet need in the market. Market Key Trends: One key trend in the Cholangiocarcinoma Market is the increasing focus on precision medicine and targeted therapies. Precision medicine involves tailoring treatment plans based on an individual's genetic makeup, allowing for more personalized and effective treatments. Several pharmaceutical companies are investing in research and development to identify specific genetic mutations and biomarkers associated with Cholangiocarcinoma to develop targeted therapies. For example, Incyte Corporation and QED Therapeutics are conducting clinical trials for their targeted therapy, pemigatinib, which has shown promising results in patients with locally advanced or metastatic Cholangiocarcinoma. PEST Analysis: - Political: Government initiatives and regulations play a crucial role in the development and availability of treatments for Cholangiocarcinoma. Governments are increasingly focusing on improving cancer care and funding research programs. - Economic: The economic impact of Cholangiocarcinoma is significant, as it requires long-term treatment and care. The high cost of treatment options and supportive care pose challenges for patients and healthcare systems. - Social: The increasing awareness about Cholangiocarcinoma among the general population and healthcare professionals is driving early detection and diagnosis. Support groups and patient advocacy organizations are providing support and resources to patients and their families. - Technological: Advances in diagnostic technologies, such as molecular testing and imaging techniques, are enabling early detection and accurate diagnosis of Cholangiocarcinoma. Additionally, the development of targeted therapies and immunotherapies is revolutionizing the treatment landscape for this aggressive cancer. Key Takeaways: In terms of market size, the global Cholangiocarcinoma market is expected to witness high growth, exhibiting a CAGR of 12.8% over the forecast period, due to increasing incidences of the disease. The rising prevalence of risk factors such as primary sclerosing cholangitis (PSC), hepatitis B and C infections, and exposure to certain chemicals and toxins are contributing to the growing incidence of Cholangiocarcinoma. Moreover, the lack of effective treatment options for this aggressive cancer creates opportunities for pharmaceutical companies to develop innovative therapies to improve patient outcomes. Key players operating in the global Cholangiocarcinoma market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc. These companies are focusing on strategic collaborations, clinical trials, and research and development activities to develop effective treatment options for Cholangiocarcinoma.
0 notes
kritikarehani · 5 years ago
Photo
Tumblr media
Symptoms associated with Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC) is a condition that affects the bile ducts. It occurs because of inflammation in the bile ducts (cholangitis) that leads to scarring (sclerosis) and narrowing of the ducts. As a result, bile cannot be released to the gallbladder and small intestine, and it builds up in the liver.
Primary Sclerosing Cholangitis is thought to arise from a combination of genetic and environmental factors. Researchers believe that genetic changes play a role in this condition because it often occurs in several members of a family and because immediate family members of someone with primary sclerosing cholangitis have an increased risk of developing the condition.  
The symptoms associated with PSC include fatigue and itching (pruritus), followed by yellowing of the skin, mucous membranes, and whites of the eyes (jaundice). Other symptoms may include losing weight without trying, poor appetite, fever, and pain in the abdomen.
Source: https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-market
0 notes
delicatemagazinedreamer · 4 years ago
Text
Primary Sclerosing Cholangitis Market  2021 Scope, Size and Precise Outlook
Tumblr media
Market Scope and Size for Primary Sclerosing Cholangitis
Sclerosing cholangitis is divided into four categories: type, treatment, symptom control, and end user. The growth of these sectors will aid you in analysing meagre growth segments in the industries, as well as providing users with a comprehensive Primary Sclerosing Cholangitis Market overview and industry insights to aid them in making strategic decisions for core market application identification.
Classic PSC, small-duct PSC, and PSC associated with autoimmune hepatitis are the three types of primary sclerosing cholangitis. The primary sclerosing cholangitis market is divided into ursodeoxycholic acid, obeticholic acid, methotrexate, corticosteroids, and other therapeutic types based on treatment type. Antihistamines, cholestyramine, antibacterials, opioid antagonists, colestipol, and others make up the Primary Sclerosing Cholangitis Market, which is segmented based on symptom control. The market for primary sclerosing cholangitis is divided into three categories based on the end user: hospital pharmacies, community pharmacies, and specialty pharmacies.
Read more @ https://creativeedge16.blogspot.com/2021/12/primary-sclerosing-cholangitis-market.html
0 notes